semaglutide obesity phase 3 Efficacy and safety of once-weekly 2·4 mg versus placebo in people with and prediabetes (STEP 10): a randomised, double-blind, placebo-controlled, multicentre trial Semaglutide 2.4-mg Injection as a

Sodhi, M., Rezaeianzadeh, R., Kezouh, A., et al

A thorough medicines reconciliation is important before and during treatment

In vivo and in vitro models of PD demonstrated that exendin-4 ameliorated behavioral deficits and reduced -synuclein pathology, and enhanced autophagy via restoration of PI3K/Akt/mammalian target of rapamycin (mTOR) signaling [84]

These trials demonstrated significant weight loss in patients treated with Mounjaro compared to placebo

Ethical approval for the validation cohort was obtained from the Institutional Review Board of Chang Gung Memorial Hospital (No: 202201889B0)

Nutritional management may therefore be more appropriately framed as stabilization of rate-limiting metabolic modules rather than post hoc correction of overt deficiency (Fig